SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction
|(Address of Principal Executive Offices)||(Zip Code)|
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|Item 5.02.|| |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 16, 2020, Mani Mohindru, Ph.D. was appointed to the Board of Directors (the “Board”) of CytomX Therapeutics, Inc. (the “Company”), effective December 16, 2020, as a Class I director, with an initial term expiring at the Company’s 2022 annual meeting of stockholders, filling a vacancy.
Dr. Mohindru will receive the Company’s standard non-employee director compensation as described under “Director Compensation” in the Company’s preliminary proxy statement filed with the Securities and Exchange Commission on April 17, 2020. Pursuant to this program, upon appointment to the Board, Dr. Mohindru will receive an option under the Company’s 2015 Equity Incentive Plan to purchase 40,000 shares of the Company’s common stock with an exercise price of the closing price of the Company’s common stock on December 16, 2020, the effective date of Dr. Mohindru’s appointment. The option will vest and become exercisable as to 1/36th of the shares subject to the option on each monthly anniversary of the date of appointment to the Board, subject to Dr. Mohindru’s continued service to the Company through each applicable vesting date.
In connection with Dr. Mohindru’s appointment to the Board, the Company will enter into an indemnification agreement with Dr. Mohindru in accordance with the Company’s standard practice and pursuant to the form previously approved by the Board and the Company’s stockholders, which form was filed as Exhibit 10.16 to the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on August 28, 2015.
There have not been any transactions since the beginning of the Company’s last fiscal year, nor are there any proposed transactions, in which the Company was or is to be a participant involving amounts exceeding $120,000 and in which Dr. Mohindru had or will have a direct or indirect material interest. There are no arrangements or understandings between Dr. Mohindru and the Company or any other persons pursuant to which Dr. Mohindru was appointed as a director of the Company.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|CYTOMX THERAPEUTICS, INC.|
|Date: December 22, 2020||By:|
SVP, General Counsel